Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.64
+0.93 (5.57%)
At close: Mar 9, 2026, 4:00 PM EDT
17.64
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:46 PM EDT
Sarepta Therapeutics Revenue
In the year 2025, Sarepta Therapeutics had annual revenue of $2.20B with 15.58% growth. Sarepta Therapeutics had revenue of $442.93M in the quarter ending December 31, 2025, a decrease of -32.73%.
Revenue (ttm)
$2.20B
Revenue Growth
+15.58%
P/S Ratio
0.82
Revenue / Employee
$2,632,619
Employees
835
Market Cap
1.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.20B | 296.26M | 15.58% |
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSRPT News
- 5 days ago - Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 10 days ago - Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program - Business Wire
- 11 days ago - Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress - Business Wire
- 11 days ago - Sarepta CEO To Jump Ship After 'Tumultuous' Year - Benzinga
- 11 days ago - Sarepta Therapeutics CEO Ingram to retire by year end - Reuters
- 11 days ago - Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments - Business Wire
- 13 days ago - Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan - Business Wire